Browse the evidence

Bariatric surgery significantly reduces the incidence of mortality and cardiovascular diseases compared to best non-surgical care in patients with obesity.

Bariatric surgery offers a dramatic reduction in mortality and cardiovascular disease risk compared to non-surgical weight loss methods. For patients with obesity, surgery is the most effective intervention for long-term survival and cardiovascular health.

Dysfunctional adipose tissue, particularly visceral fat, drives CKM syndrome by secreting proinflammatory and prooxidative products that damage arterial, cardiac, and kidney tissues, leading to insulin resistance and systemic inflammation.

Excess visceral fat is not just stored energy; it actively releases harmful substances that damage your heart, kidneys, and blood vessels. Managing your weight, specifically reducing visceral fat, is a key medical strategy to reduce inflammation and protect your organs.

Physiological adaptations to weight loss, including slowed resting metabolic rate (RMR) and increased hunger hormones, actively defend a higher body weight 'set-point' and promote weight regain.

After you lose weight, your body will fight to get it back by slowing your metabolism and increasing hunger. This is a biological 'set-point' defense, not a lack of willpower. To maintain weight loss, you must accept that you will need to be more vigilant about food intake and exercise than before, as your body is biologically programmed to regain the weight.

The carbohydrate-insulin model, which posits that high carbohydrate intake causes hyperinsulinemia leading to fat storage and weight gain, is experimentally falsified because low-carbohydrate diets fail to produce the expected fat loss or sustained increase in energy expenditure.

Do not rely on the carbohydrate-insulin model to explain weight loss. Low-carb diets do not inherently increase energy expenditure or fat loss compared to other diets when calories are matched. Focus on sustainable dietary patterns.

Metabolic surgery reduces the risk of microvascular and macrovascular complications, as well as all-cause mortality, compared to non-surgical treatment in T2D patients.

Beyond weight loss, metabolic surgery significantly lowers the risk of diabetes-related organ damage (eyes, kidneys, nerves) and reduces the risk of early death compared to managing diabetes with medication and lifestyle changes alone.

Leptin regulates glucose homeostasis through direct actions on POMC neurons, but does not regulate food intake or energy balance through direct actions on these same neurons.

Understanding that leptin's effect on blood sugar is distinct from its effect on hunger helps explain why leptin therapy fails for weight loss in most obese individuals (who are leptin resistant) but might still have metabolic benefits. It shifts focus from 'blocking hunger' to 'metabolic flexibility' and non-POMC pathways.

Acute postexercise elevations in systemic anabolic hormones (testosterone, growth hormone, IGF-1) are neither necessary nor sufficient to stimulate muscle protein synthesis or drive resistance exercise training-induced hypertrophy.

Stop worrying about the exact time of day you train or trying to manipulate your hormones for better gains. Whether you train in the morning or evening, or whether your hormones fluctuate during your menstrual cycle, does not significantly change your ability to build muscle. Focus on consistent, progressive resistance training rather than trying to 'optimize' your hormonal environment.

Obesity is a biologic disorder caused by alterations in CNS pathways controlling energy balance, not a lifestyle failure remediable by willpower alone.

Stop blaming yourself for your weight. Your body is fighting you due to biological mechanisms, not just willpower. Seek medical treatment for obesity just as you would for high blood pressure.

GLP-1 therapy is associated with significant gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) which are dose-dependent and can lead to discontinuation, although most side effects decrease with continued use.

You will likely experience some gastrointestinal side effects like nausea, diarrhea, or constipation, especially when you start the medication or increase the dose. These symptoms often improve over time. Talk to your doctor about managing these side effects through diet and slow dose titration.

Obesity is fundamentally driven by a disruption in energy balance, mediated by central nervous system resistance to leptin and insulin, and dysregulation of the reward system.

Obesity involves biological resistance to satiety signals (leptin/insulin) and reward dysregulation, meaning willpower alone is often insufficient. Medical interventions that bypass or enhance these signals are often necessary.

Obesity is a chronic, progressive, relapsing, and treatable multi-factorial neurobehavioral disease, not just a lifestyle choice.

Understand that obesity is a disease with biological drivers, not just a failure of will. This reduces self-blame and opens the door to effective medical and lifestyle interventions.

SGLT2 inhibitors provide consistent cardiovascular benefits (reduced mortality and morbidity) across all BMI classes in heart failure, with no mediating effect of obesity on their efficacy.

If you have heart failure, SGLT2 inhibitors (like Dapagliflozin or Empagliflozin) are a standard, highly effective treatment that works regardless of your weight. They reduce the risk of hospitalization and death. Discuss starting these with your doctor if you are not already on them.

Genetic variants, particularly in the MC4R, FTO, and LEP/LEPR genes, significantly influence susceptibility to obesity, affecting appetite regulation, energy expenditure, and fat storage.

Genetics play a significant role in obesity risk. If you have a family history of obesity, you may have a higher predisposition. However, this does not mean weight management is impossible; tailored medical and lifestyle strategies can be highly effective.

Higher genetically predicted lifelong BMI causally increases all-cause mortality, with the effect substantially mediated through diabetes.

In this population, higher lifelong BMI significantly increases the risk of premature death, largely by increasing the risk of diabetes. Managing weight and blood sugar are critical for longevity.

Higher genetically predicted BMI causally increases the risk of renal, acute diabetic crisis, and infective deaths.

Higher BMI is strongly linked to death from kidney disease, severe diabetic episodes, and infections. Preventing these outcomes requires addressing underlying metabolic health.

Semaglutide provides robust cardiovascular risk reduction (MACE) in patients with Type 2 Diabetes and established cardiovascular disease, independent of glycemic control improvements.

If you have obesity and established heart disease, semaglutide (2.4mg weekly) significantly reduces your risk of major adverse cardiovascular events (MACE), even if you do not have diabetes. This benefit is driven by weight loss and cardiometabolic improvement, not just blood sugar control.

Obesity drives insulin resistance and type 2 diabetes through the accumulation of free fatty acids and pro-inflammatory cytokines in non-adipose tissues, which activate kinases (PKC, JNK, IKKβ) that inhibit insulin receptor signaling.

If you have obesity, your risk for type 2 diabetes is significantly higher due to biological changes in your fat tissue and blood. This isn't just about 'eating less'; it's about how your body processes energy. Addressing obesity through sustainable lifestyle changes can mitigate these specific biological risks.

High systolic blood pressure (SBP) is a leading metabolic risk factor globally, contributing to 7.8% of total disability-adjusted life-years (DALYs) in 2021, with an increasing annual exposure rate of 1.8%.

High blood pressure is a major driver of global disease burden. Regular monitoring and management are crucial for long-term health.

Inflammation and disease burden are critical etiologic criteria for malnutrition, contributing to altered metabolism, increased muscle catabolism, and adverse outcomes.

Malnutrition isn't just about not eating enough; active disease and inflammation can cause muscle loss and metabolic changes even if food intake is normal. Diagnosis must account for these inflammatory drivers.

Muscle atrophy in catabolic conditions (cancer, diabetes, inactivity) is driven by the upregulation of 'atrogines' like MuRF1 and Atrogin-1, which target structural proteins for degradation via the ubiquitin-proteasome system.

Muscle loss during illness or inactivity is not just 'passive'; your body actively activates specific genes (like MuRF1 and Atrogin-1) to break down muscle protein. This process is driven by stress hormones and inflammation. Preventing or reversing this requires addressing the underlying catabolic drivers, not just 'resting'.

Men have a higher prevalence of type 2 diabetes than women, particularly in middle-aged populations, due to greater visceral adiposity, ectopic fat accumulation, and lower insulin sensitivity.

Men are biologically more susceptible to type 2 diabetes than women, especially between ages 35 and 69. This is largely due to storing fat around the organs (visceral fat) rather than under the skin. Men should prioritize regular screening for blood sugar and insulin resistance, as their bodies are less forgiving of poor metabolic health than women's.

Persistent hyperglycemia accelerates endogenous AGE formation through the Maillard reaction and dicarbonyl stress, leading to RAGE activation, oxidative stress, and insulin resistance.

Maintaining blood glucose levels within target ranges is critical to preventing the formation of endogenous AGEs and subsequent tissue damage.

Palmitic acid is essential for physiological functions including maintaining membrane fluidity, protein palmitoylation, and lung surfactant activity (DPPC), and its deficiency can impair lung function.

Palmitic acid is not just 'bad fat'; it is essential for your lungs (surfactant), cell membranes, and protein signaling. Your body makes it and needs it. The problem arises not from its presence, but from excess production due to sugar and calorie overload.

Adipose tissue acts as an endocrine organ, secreting hormones like leptin and adiponectin that regulate systemic metabolism, insulin sensitivity, and energy expenditure.

Understand that your fat cells send signals to your brain and other organs. Healthy fat levels help regulate hunger (leptin) and insulin sensitivity (adiponectin). Disrupting these signals through extreme dieting or obesity can lead to metabolic dysfunction.